4-oxo-5-succinimido-valeric acid | 103452-43-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: 4-oxo-5-succinimido-valeric acid
• 英文别名: 4-Oxo-5-succinimido-valeriansaeure；5-(2,5-Dioxopyrrolidin-1-yl)-4-oxopentanoic acid
• CAS: 103452-43-3
• 化学式: C₉H₁₁NO₅
• 分子量: 213.19
• InChiKey: KTACEMRFLNCXPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  91.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-oxo-5-succinimido-valeric acid 在 sodium hydroxide 作用下， 生成 5-(3-carboxy-propionylamino)-4-oxo-valeric acid
  参考文献：
  名称：

  δ-琥珀酰胺基果酸及其相关化合物的合成

  摘要：

  DOI：

  10.1039/jr9540001820
• 作为产物：
  描述：

  methyl 5-chloro-4-oxopentanoate 在 盐酸 、 水 、 potassium carbonate 、 N,N-二甲基甲酰胺 作用下， 生成 4-oxo-5-succinimido-valeric acid
  参考文献：
  名称：

  δ-琥珀酰胺基果酸及其相关化合物的合成

  摘要：

  DOI：

  10.1039/jr9540001820

文献信息

• METHODS FOR CONJUGATION OF OLIGOSACCHARIDES OR POLYSACCHARIDES TO PROTEIN CARRIERS THROUGH OXIME LINKAGES VIA 3-DEOXY-D-MANNO-OCTULSONIC ACID
  申请人：Kubler-Kielb Joanna

  公开号：US20100158937A1

  公开（公告）日：2010-06-24

  Methods for preparing an oligosaccharide-protein carrier immunogenic conjugate or a polysaccharide-protein carrier immunogenic conjugate. The methods include obtaining an oligosaccharide or polysaccharide having a KDO moiety located at the terminal reducing end of the oligosaccharide or polysaccharide that includes a carbonyl functional group; and reacting the carbonyl functional group of the KDO moiety with an aminooxylated protein carrier molecule resulting in a conjugate that includes a covalent oxime bond between the oligosaccharide and the protein carrier or the polysaccharide and the protein carrier.

  制备寡糖-蛋白质载体免疫原结合物或多糖-蛋白质载体免疫原结合物的方法。该方法包括获取一个寡糖或多糖，在其末端还原端位置包含一个KDO基团，该基团包括一个羰基官能团；并将KDO基团的羰基官能团与氨氧化蛋白质载体分子反应，从而形成结合物，其中寡糖和蛋白质载体或多糖和蛋白质载体之间包括共价的肟键。
• Implant coated with multi-domain amphipathic helical peptides and methods of their use
  申请人：The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services

  公开号：EP2218736A1

  公开（公告）日：2010-08-18

  Disclosed herein are peptides or peptide analogs with multiple amphipathic a-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic a-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein.

  本文公开了具有多个两亲性 a-helical 结构域的肽或肽类似物，它们可通过 ABCA1 依赖性途径促进脂质从细胞中流出。本文还提供了使用多结构域两性 a-helical 肽或肽类似物治疗或抑制血脂异常疾病的方法。本文还公开了鉴定能促进细胞ABCA1依赖性脂质外流的非细胞毒性多肽的方法。
• Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Services

  公开号：US10301377B2

  公开（公告）日：2019-05-28

  Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.

  本文提供了诱导受试者对中东呼吸综合征冠状病毒（MERS-CoV）产生免疫应答的方法。在几个实施方案中，免疫应答是一种保护性免疫应答，可抑制或预防受试者感染 MERS-CoV。还提供了重组 MERS-CoV 多肽和编码它们的核酸分子。此外，还公开了与 MERS-CoV S 蛋白特异性结合的中和抗体及其抗原结合片段。例如，这些抗体和抗原结合片段可用于检测样本或受试者体内的 MERS-CoV S 蛋白，以及预防和治疗受试者感染 MERS-CoV 的方法。
• Methods for preparing immunogenic conjugates
  申请人：Schneerson Rachel

  公开号：US20050271675A1

  公开（公告）日：2005-12-08

  Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazino-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage.

  制造免疫原性共轭物的方法，该共轭物包括与载体共价连接的合体或抗原。这些方法包括：将第一制剂与二酰肼反应，得到酰肼修饰的第一制剂，其中第一制剂是单体、抗原或载体；将第二制剂与苯甲醛化合物反应，得到苯甲醛修饰的第二制剂，其中第二制剂是单体、抗原或载体，前提是第一制剂或第二制剂是载体；使肼改性的第一制剂与苯甲醛改性的第二制剂反应，产生免疫原性共轭物，该共轭物包括通过腙连接与载体共价连接的单体或抗原。
• Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
  申请人：Schneerson Rachel

  公开号：US20060134143A1

  公开（公告）日：2006-06-22

  Immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacilli are provided that include immunogenic conjugates of a poly-γ-glutamic acid (γPGA) polypeptide of B. anthracis, or of another Bacillus that expresses a γPGA polypeptide. The γPGA conjugates elicit an effective immune response against B. anthracis, or against another Bacillus, in mammalian hosts to which the conjugates are administered.

  诱发针对炭疽杆菌的免疫应答的免疫原性组合物和方法 炭疽杆菌 和其他杆菌产生免疫应答的免疫原性组合物和方法。 炭疽杆菌 或其他 芽孢杆菌 表达 γPGA 多肽的芽孢杆菌。γPGA共轭物可引起针对以下细菌的有效免疫反应 炭疽杆菌 或另一种 炭疽杆菌的免疫反应、 γPGA共轭物在哺乳动物宿主体内引起针对炭疽杆菌或其他芽孢杆菌的有效免疫反应。